TY - JOUR
T1 - Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan
AU - Working Group on Diagnostic Criteria for Refractory Optic Neuritis Based on Neuroimmunological Perspective
AU - Ishikawa, Hitoshi
AU - Kezuka, Takeshi
AU - Shikishima, Keigo
AU - Yamagami, Akiko
AU - Hiraoka, Miki
AU - Chuman, Hideki
AU - Nakamura, Makoto
AU - Hoshi, Keika
AU - Goseki, Toshiaki
AU - Mashimo, Kimiyo
AU - Mimura, Osamu
AU - Yoshitomi, Takeshi
AU - Tanaka, Keiko
AU - Sugasawa, Jun
AU - Fujikado, Takashi
AU - Okubo, Shinji
AU - Watanabe, Toshiki
AU - Aomatsu, Keiichi
AU - Aihara, Hajime
AU - Suzuki, Tone
AU - Ueki, Satoshi
AU - Miki, Atsushi
AU - Shinmei, Yasuhiro
AU - Takeuchi, Masaru
AU - Fukusima, Atsuki
AU - Hata, Masayuki
AU - Yanai, Ryoji
AU - Sonoda, Kohei
AU - Senoo, Tadashi
AU - Mizota, Atsushi
AU - Kaneko, Yutaka
AU - Kiyosawa, Motohiro
AU - Ueda, Nobuhiko
AU - Higashiyama, Tomoaki
AU - Nakamagoe, Kiyotaka
AU - Akiyama, Hisanao
N1 - Funding Information:
Supported by the Ministry of Health, Labour and Welfare (Grant-in-aid for Scientific Research no.: H27-Nanchito-(Nan)-Ippan-023). The sponsor or funding organization had no role in the design or conduct of this research.
Publisher Copyright:
© 2019 American Academy of Ophthalmology
PY - 2019/10
Y1 - 2019/10
N2 - Purpose: To elucidate the clinical and epidemiologic characteristics of optic neuritis in Japan. Design: Multicenter cross-sectional, observational cohort study. Participants: A total of 531 cases of unilateral or bilateral noninfectious optic neuritis identified in 33 institutions nationwide in Japan. Methods: Serum samples from patients with optic neuritis were tested for anti–aquaporin-4 antibodies (AQP4-Abs) and anti–myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) using a cell-based assay and were correlated with the clinical findings. Main Outcome Measures: Antibody positivity, clinical and radiologic characteristics, and visual outcome. Results: Among 531 cases of optic neuritis, 12% were AQP4-Ab positive, 10% were MOG-Ab positive, 77% were negative for both antibodies (double-negative), and 1 case was positive for both antibodies. Pretreatment visual acuity (VA) worsened to more than a median 1.0 logarithm of the minimum angle of resolution (logMAR) in all groups. After steroid pulse therapy (combined with plasmapheresis in 32% of patients in AQP4-Ab–positive group), median VA improved to 0.4 logMAR in the AQP4-Ab–positive group, 0 logMAR in the MOG-Ab–positive group, and 0.1 logMAR in the double-negative group. The AQP4-Ab–positive group showed a high proportion of females, exhibited diverse visual field abnormalities, and demonstrated concurrent spinal cord lesions on magnetic resonance imaging (MRI) in 22% of the patients. In the MOG-Ab–positive group, although posttreatment visual outcome was good, the rates of optic disc swelling and pain with eye movement were significantly higher than those in the AQP4-Ab–positive and double-negative groups. However, most cases showed isolated optic neuritis lesions on MRI. In the double-negative group, 4% of the patients had multiple sclerosis. Multivariate logistic regression analysis of all participants identified age and presence of antibodies (MOG-Ab and AQP4-Ab) as significant factors affecting visual outcome. Conclusions: The present large-scale cohort study revealed the clinicoepidemiologic features of noninfectious optic neuritis in Japan. Anti–aquaporin-4 antibody–positive optic neuritis has poor visual outcome. In contrast, MOG-Ab positive cases manifested severe clinical findings of optic neuritis before treatment, but few showed concurrent lesions in sites other than the optic nerve and generally showed good treatment response with favorable visual outcome. These findings indicate that autoantibody measurement is useful for prompt diagnosis and proper management of optic neuritis that tends to become refractory.
AB - Purpose: To elucidate the clinical and epidemiologic characteristics of optic neuritis in Japan. Design: Multicenter cross-sectional, observational cohort study. Participants: A total of 531 cases of unilateral or bilateral noninfectious optic neuritis identified in 33 institutions nationwide in Japan. Methods: Serum samples from patients with optic neuritis were tested for anti–aquaporin-4 antibodies (AQP4-Abs) and anti–myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) using a cell-based assay and were correlated with the clinical findings. Main Outcome Measures: Antibody positivity, clinical and radiologic characteristics, and visual outcome. Results: Among 531 cases of optic neuritis, 12% were AQP4-Ab positive, 10% were MOG-Ab positive, 77% were negative for both antibodies (double-negative), and 1 case was positive for both antibodies. Pretreatment visual acuity (VA) worsened to more than a median 1.0 logarithm of the minimum angle of resolution (logMAR) in all groups. After steroid pulse therapy (combined with plasmapheresis in 32% of patients in AQP4-Ab–positive group), median VA improved to 0.4 logMAR in the AQP4-Ab–positive group, 0 logMAR in the MOG-Ab–positive group, and 0.1 logMAR in the double-negative group. The AQP4-Ab–positive group showed a high proportion of females, exhibited diverse visual field abnormalities, and demonstrated concurrent spinal cord lesions on magnetic resonance imaging (MRI) in 22% of the patients. In the MOG-Ab–positive group, although posttreatment visual outcome was good, the rates of optic disc swelling and pain with eye movement were significantly higher than those in the AQP4-Ab–positive and double-negative groups. However, most cases showed isolated optic neuritis lesions on MRI. In the double-negative group, 4% of the patients had multiple sclerosis. Multivariate logistic regression analysis of all participants identified age and presence of antibodies (MOG-Ab and AQP4-Ab) as significant factors affecting visual outcome. Conclusions: The present large-scale cohort study revealed the clinicoepidemiologic features of noninfectious optic neuritis in Japan. Anti–aquaporin-4 antibody–positive optic neuritis has poor visual outcome. In contrast, MOG-Ab positive cases manifested severe clinical findings of optic neuritis before treatment, but few showed concurrent lesions in sites other than the optic nerve and generally showed good treatment response with favorable visual outcome. These findings indicate that autoantibody measurement is useful for prompt diagnosis and proper management of optic neuritis that tends to become refractory.
UR - http://www.scopus.com/inward/record.url?scp=85066957958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066957958&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2019.04.042
DO - 10.1016/j.ophtha.2019.04.042
M3 - Article
C2 - 31196727
AN - SCOPUS:85066957958
SN - 0161-6420
VL - 126
SP - 1385
EP - 1398
JO - Ophthalmology
JF - Ophthalmology
IS - 10
ER -